期刊文献+

舒普深和泰能经验治疗急诊老年肺部革兰阴性菌感染合并呼吸衰竭对比分析 被引量:3

Comparative analysis on effective of cefoperazone and imipenem in treatment of G-bacteria infection in elderly patients
下载PDF
导出
摘要 目的比较舒普深和泰能经验治疗急诊老年肺部革兰阴性菌感染合并呼吸衰竭的疗效.方法自北大医院急诊科留观病房2001年10月-2003年3月间收治急诊老年肺部革兰阴性菌感染合并呼吸衰竭病例中,选取入院后经验首选舒普深(共57例)或泰能(共28例)治疗者,对其3 d后病情严重程度评分减分、革兰阴性细菌阳性培养结果进行评价.结果舒普深和泰能二者治疗急诊老年肺部革兰阴性菌感染合并呼吸衰竭病情严重程度评分减分无显著差异、革兰阴性细菌阳性培养结果的药敏结果敏感比率亦相当.结论治疗急诊老年肺部革兰阴性菌感染合并呼吸衰竭,经验首选舒普深和泰能疗效相仿. comparison on the effective of cefoperazone and imipenem in the treatment of the elderly patients with G- bacteria pulmonary infection complicated with RF. Elderly patients,hospitalized in observe ward during Oct, 2001~March, 2003, suffered from pulmonary infection complicated with RF,characterized by G- bacteria, entered into the trial, 57 patients of which treated with cefo, 28 patients with imi, the severe score and bacteria culture results was evaluated after 3 days treatment. The score after treatment between two groups was significant different, the ratio of drug sensitivity on bacteria culture no significant difference. [Conclusion] The effective of two drugs on the treatment of empirical bacteria pulmonary infection complicated with RF in elderly patients is similar.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2005年第2期273-274,277,共3页 China Journal of Modern Medicine
关键词 舒普深 泰能 老年 肺部感染 cefoperazone imipenem elderly patients pulmonary infection
  • 相关文献

参考文献5

二级参考文献47

  • 1汪复,张敬德,朱德妹,王宇倩,周乐,张婴元.Du6859a及其他新的氟喹诺酮类药物的体外抗菌活性[J].中国抗生素杂志,1996,21(3):214-219. 被引量:13
  • 2[1]CDC, National Nosocomial Infections Surveillance(NNIS) System report, Data summary from October 1986-April 1998; issyed June 1998[J]. Am J Infect Control, 1998,26: 522-533
  • 3[2]Gales AC, Jones RN, Turnidge J, et al. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999[J].Clin Infect Dis,2001,32(Suppl 2): 146-155
  • 4[3]Harris AD, Smith D, Johnson JA, et al. Risk factors for imipenem-resistant pseudomonas aeruginosa among hospitalized patients [J]. Clin Infect Dis, 2002,34: 340-345
  • 5[4]Busher KH, Cullmann W, Dick W, et al. Imipenem resistance in pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein[J]. Antimicrob Agents Chemother,1987,31 : 703-708
  • 6[5]Pai H, Kim J, Kim J, et al. Carbapenem resistance mechanisms in pseudomonas aeruginosa clinical isolates [J]. Antimicrob agents chemother,2001,45:480-484
  • 7Vannuffel P, Cocito C. Mechanism of action of streptogramins and macrolides[J]. Drugs, 1996, 51(suppl 1):20-30
  • 8Pechere JC. Streptogramins-a unique class of antibiotics[J]. Drugs 1996, 51(suppl 1): 13-19
  • 9Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium[J]. J.Antimicrob Chemother, 1999, 44: 251-261
  • 10Diekema DI, Jones RN. Oxazolidinones: a review[J]. Drugs, 2000, 59: 7-16

共引文献89

同被引文献11

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部